{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:21:28Z","timestamp":1780442488305,"version":"3.54.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.medcli.2022.04.004","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T21:17:21Z","timestamp":1654636641000},"page":"289-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hepatitis autoinmune: retos y novedades"],"prefix":"10.1016","volume":"159","author":[{"given":"Ignasi","family":"Olivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Rodr\u00edguez-Tajes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carlota","family":"Londo\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2022.04.004_bib0325","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: Autoimmune hepatitis","volume":"63","author":"Lohse","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0330","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2022.04.004_bib0335","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/liv.14480","article-title":"Incidence, prevalence and mortality of autoimmune hepatitis in England 1997-2015. A population-based cohort study","volume":"40","author":"Gr\u00f8nb\u00e6k","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.medcli.2022.04.004_bib0340","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/gutjnl-2020-322362","article-title":"Recent advances in clinical practice: Epidemiology of autoimmune liver diseases","volume":"70","author":"Trivedi","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.medcli.2022.04.004_bib0345","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-pathol-020117-043534","article-title":"Cellular and molecular mechanisms of autoimmune hepatitis","volume":"13","author":"Webb","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0350","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jaut.2016.05.005","article-title":"CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease","volume":"72","author":"Liberal","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.medcli.2022.04.004_bib0355","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41423-020-00529-z","article-title":"Shared and distinct roles of T peripheral helper and T follicular helper cells in human diseases","volume":"18","author":"Yoshitomi","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0360","doi-asserted-by":"crossref","DOI":"10.1007\/s12016-021-08888-9","article-title":"Autoimmune hepatitis: Serum autoantibodies in clinical practice","author":"Terziroli Beretta-Piccoli","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0365","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10620-010-1501-1","article-title":"Performance parameters of the conventional serological markers for autoimmune hepatitis","volume":"56","author":"Czaja","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.medcli.2022.04.004_bib0370","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s10620-011-2017-z","article-title":"Autoantibody-negative autoimmune hepatitis","volume":"57","author":"Czaja","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.medcli.2022.04.004_bib0375","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","article-title":"Liver autoimmune serology: A consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group","volume":"41","author":"Vergani","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0380","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fimmu.2018.00609","article-title":"Autoantibodies in autoimmune liver disease\u2014Clinical and diagnostic relevance","volume":"9","author":"Sebode","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0385","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/hep.24080","article-title":"Autoimmune acute liver failure: Proposed clinical and histological criteria","volume":"53","author":"Stravitz","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2022.04.004_bib0390","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2022.04.004_bib0395","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1007\/s10620-006-9665-4","article-title":"Corticosteroid-responsive cryptogenic chronic hepatitis: Evidence for seronegative autoimmune hepatitis","volume":"52","author":"Gassert","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.medcli.2022.04.004_bib0400","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0025-6196(12)62106-5","article-title":"Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis","volume":"65","author":"Czaja","year":"1990","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.medcli.2022.04.004_bib0405","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hep.32134","article-title":"Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis","volume":"75","author":"Taubert","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2022.04.004_bib0410","doi-asserted-by":"crossref","first-page":"100149","DOI":"10.1016\/j.jhepr.2020.100149","article-title":"Approach to the patient with acute severe autoimmune hepatitis","volume":"2","author":"Rahim","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.medcli.2022.04.004_bib0415","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jhep.2014.05.021","article-title":"Prognosis of acute severe autoimmune hepatitis (AS-AIH): The role of corticosteroids in modifying outcome","volume":"61","author":"Yeoman","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0420","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/jclinpath-2016-204271","article-title":"Acute presentation of autoimmune hepatitis: A multicentre study with detailed histological evaluation in a large cohort of patients","volume":"70","author":"Nguyen Canh","year":"2017","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0425","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis","volume":"51","author":"Bj\u00f6rnsson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2022.04.004_bib0430","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4254\/wjh.v6.i4.160","article-title":"Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease","volume":"6","author":"Castiella","year":"2014","journal-title":"World J Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0435","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: Drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0440","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.24481","article-title":"The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury","volume":"54","author":"Suzuki","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2022.04.004_bib0445","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jhep.2021.12.041","article-title":"Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group","volume":"76","author":"Pape","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0450","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/apt.16035","article-title":"Review article: Experimental therapies in autoimmune hepatitis","volume":"52","author":"Halliday","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.medcli.2022.04.004_bib0455","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2022.04.004_bib0460","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jhep.2020.07.023","article-title":"Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group","volume":"73","author":"Lohse","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0465","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cgh.2015.09.037","article-title":"Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance","volume":"14","author":"H\u00fcbener","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0470","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cgh.2007.02.030","article-title":"Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy","volume":"5","author":"Inductivo-Yu","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0475","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1155\/2010\/891252","article-title":"Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy","volume":"24","author":"Sharzehi","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0480","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","article-title":"Mycophenolate mofetil as second line therapy in autoimmune hepatitis?","volume":"103","author":"Hennes","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0485","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1007\/s10620-008-0632-0","article-title":"Mycophenolate mofetil for autoimmune hepatitis: A single practice experience","volume":"54","author":"Wolf","year":"2009","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.medcli.2022.04.004_bib0490","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04727.x","article-title":"The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes","volume":"34","author":"Baven-Pronk","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.medcli.2022.04.004_bib0495","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jceh.2014.05.003","article-title":"Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-An observational study","volume":"4","author":"Jothimani","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0500","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.cgh.2017.06.001","article-title":"Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis","volume":"15","author":"Efe","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0505","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2017.09.063","article-title":"Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy","volume":"16","author":"Roberts","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0510","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.dld.2018.10.004","article-title":"Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine","volume":"51","author":"Giannakopoulos","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.medcli.2022.04.004_bib0515","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/hep.25760","article-title":"Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis","volume":"56","author":"Dhaliwal","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2022.04.004_bib0520","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jhep.2021.03.023","article-title":"Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates","volume":"75","author":"Candels","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0525","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.mcg.0000139050.67178.be","article-title":"Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis","volume":"38","author":"Aqel","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0530","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1478-3231.2005.01107.x","article-title":"Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: The Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus","volume":"25","author":"Chatur","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.medcli.2022.04.004_bib0535","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3748\/wjg.v13.i23.3232","article-title":"Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis","volume":"13","author":"Larsen","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0540","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2036.2011.04749.x","article-title":"Use of tacrolimus in the treatment of autoimmune hepatitis: A single centre experience","volume":"34","author":"Tannous","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.medcli.2022.04.004_bib0545","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/00365521.2015.1095351","article-title":"Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on tacrolimus therapy","volume":"51","author":"Than","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0550","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/00365521.2016.1236398","article-title":"The use of tacrolimus in refractory autoimmune hepatitis in children and adults: A single center experience","volume":"52","author":"Al Taii","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0555","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1007\/s10620-020-06569-9","article-title":"Tacrolimus as an effective and durable second-line treatment for chronic autoimmune hepatitis: A multicentric study","volume":"66","author":"Ferre-Aracil","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.medcli.2022.04.004_bib0560","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0168-8278(05)80615-4","article-title":"Cyclosporine in the management of corticosteroid-resistant type i autoimmune chronic active hepatitis","volume":"21","author":"Sherman","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0565","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1572-0241.1999.00807.x","article-title":"Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis","volume":"94","author":"Fernandes","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0570","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1023\/A:1010683817344","article-title":"Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis","volume":"46","author":"Malekzadeh","year":"2001","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.medcli.2022.04.004_bib0575","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/hep.31597","article-title":"Long-term observation of cyclosporine as second-line therapy in adults for severe acute autoimmune hepatitis","volume":"73","author":"Noguchi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2022.04.004_bib0580","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cgh.2017.07.003","article-title":"Methotrexate therapy for autoimmune hepatitis","volume":"16","author":"Haridy","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0585","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2013\/512624","article-title":"Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy","volume":"27","author":"Burak","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0590","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jhepr.2019.10.005","article-title":"Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group","volume":"1","author":"Than","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.medcli.2022.04.004_bib0595","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2012.11.010","article-title":"Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis","volume":"58","author":"Weiler-Normann","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0600","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3109\/00365521.2014.998271","article-title":"Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use","volume":"50","author":"Ytting","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0605","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/MEG.0000000000001580","article-title":"Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: A real-world-experience","volume":"32","author":"Pape","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0610","doi-asserted-by":"crossref","DOI":"10.1002\/hep.32410","article-title":"Autoimmune hepatitis in pregnancy: Pearls and pitfalls","author":"Chung","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2022.04.004_bib0615","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.cgh.2018.12.030","article-title":"Presentation and outcomes of pregnancy in patients with autoimmune hepatitis","volume":"17","author":"Llovet","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0620","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12016-016-8583-2","article-title":"The management of autoimmune hepatitis patients with decompensated cirrhosis: Real-world experience and a comprehensive review","volume":"52","author":"Wang","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.medcli.2022.04.004_bib0625","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren's syndrome: A randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2022.04.004_bib0630","doi-asserted-by":"crossref","first-page":"100123","DOI":"10.1016\/j.jhepr.2020.100123","article-title":"Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis","volume":"2","author":"Arvaniti","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.medcli.2022.04.004_bib0635","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/hep.30059","article-title":"Low-dose interleukin-2 for refractory autoimmune hepatitis","volume":"68","author":"Lim","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2022.04.004_bib0640","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41573-019-0041-4","article-title":"Next-generation regulatory T cell therapy","volume":"18","author":"Ferreira","year":"2019","journal-title":"Nat Rev Drug Discov"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775322001828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775322001828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T10:09:56Z","timestamp":1706004596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775322001828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0025775322001828"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2022.04.004","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis autoinmune: retos y novedades","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2022.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}